King's College London: Trial to Repurpose Cancer Drug for Patients With COVID-19 Launches
May 30, 2020
May 30, 2020
LONDON, May 30 -- King's College London issued the following news release:
The trial will study the use of ruxolitinib (Novartis Pharmaceuticals), a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients, the need for intensive care and death rate.
Researchers from King's College London and Guy's and St Thomas' NHS Foundation Trust will begin the trial next week. The research has been funded by LifeArc and the Masterstroke . . .
The trial will study the use of ruxolitinib (Novartis Pharmaceuticals), a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients, the need for intensive care and death rate.
Researchers from King's College London and Guy's and St Thomas' NHS Foundation Trust will begin the trial next week. The research has been funded by LifeArc and the Masterstroke . . .